A combination of two types of therapy may be more effective in treating castration-resistant prostate cancer.
A cell-penetrating peptide developed at Vanderbilt blocks the signaling pathways that lead to lethal shock caused by bacterial infection.
Vanderbilt researchers have discovered that certain immune cells contribute to the development of hypertension, suggesting novel targets for treating the disease.
Accessibility Tools